Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

被引：117

作者：

Gurumurthy, P

Ramachandran, G

Kumar, AKH

Rajasekaran, S

Padmapriyadarsini, C

Swaminathan, S

Bhagavathy, S

Venkatesan, P

Sekar, L

Mahilmaran, A

Ravichandran, N

Paramesh, P

机构：

[1] Indian Council Med Res, TB Res Ctr, HIV AIDS Div, Madras 600031, Tamil Nadu, India

[2] Govt Hosp Thorac Med, Madras, Tamil Nadu, India

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 11期

关键词：

D O I：

10.1128/AAC.48.11.4473-4475.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs.

引用

页码：4473 / 4475

页数：3

共 19 条

[11]

KUMAR AKH, 2004, IND J PHARM

[12]

OLSON WA, 1977, CLIN CHEM, V23, P745

[13] DRUG MALABSORPTION AND RESISTANT TUBERCULOSIS IN HIV-INFECTED PATIENTS [J].